By Kelly Cloonan
Beyond Air has secured a patent for its treatment of non-tuberculous mycobacteria lung infections using gaseous nitric oxide.
The medical device and biopharmaceutical company said Thursday the patent will expire in 2038.
Chief Executive Steve Lisi said the patent strengthens the company's intellectual property portfolio and reinforces the potential of its LungFit program.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 24, 2025 17:23 ET (21:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。